BioPharma Resources

Drug Trial Radar · NCT00917735

Green Tea and Reduction of Breast Cancer Risk

Phase II, Randomized,Double-blind, Placebo-controlled, Study of the Efficacy of Green Tea Extract on Biomarkers of Breast Cancer Risk in High Risk Women With Differing Catechol-O-methyl Transferase (COMT) Genotypes

Last checked: Nov 19, 2026Latest source record: Feb 22, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,075 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,075

Actual

Start

Jul 2009

Primary completion

Jun 2014

Study completion Jun 2014

Sponsor

Lead sponsor
University of MinnesotaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Jun 10, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
Female only, from 50 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

RATIONALE: Green tea extract contains ingredients (catechins) that may lower the risk of breast cancer. PURPOSE: This phase II trial is studying how well green tea extract works in preventing breast cancer compared to a placebo in postmenopausal women with high breast density. The investigators have hypothesized that green tea consumption reduces breast cancer risk, and this effect is seen primarily in women who have the low-activity COMT genotype. The investigators will test this by evaluating the effects of green tea extract on breast cancer biomarkers including mammographic density, plasma insulin-like growth factor 1 (IGF-1), IGF binding protein 3 (IGFBP-3), estrone, estradiol, androstenedione, sex hormone binding globulin (SHBG), urinary estrogen metabolites and plasma F2-isoprostanes.

Conditions

  • Breast Cancer

Interventions

  • Green tea extract supplementDrug

    Two green tea extract capsules twice daily after breakfast and dinner for one year

  • PlaceboOther

    Two placebo capsules twice daily after breakfast and dinner for one year

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mammographic DensityTime frame: Baseline and month 12
  2. Circulating Concentrations of Reproductive Hormones Including Estrone, Estradiol, Androstenedione, Testosterone, and Sex Hormone Binding Globulin (SHBG)Time frame: Baseline and month 12
  3. Circulating Concentrations of IGF Axis Proteins Including IGF-1 and IGFBP-3Time frame: Baseline and month 12

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Fairview Southdale Breast Center

    Edina, Minnesota

  • Fairview Maple Grove Breast Center

    Maple Grove, Minnesota

  • University of Minnesota Medical Center (UMMC) Breast Clinic

    Minneapolis, Minnesota

  • Park Nicollet Institute

    Saint Louis Park, Minnesota

  • Food Science and Nutrition, University of Minnesota

    Saint Paul, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.